The company “Valenta Farm” announced that as of April 1, 2017, it ceased production of Fentropil, a popular nootropic drug in Russia. The drug was created as a stimulant for astronauts in the USSR at the Institute of Biomedical Problems.
The description of the drug says that Fenotropil (fonotracetam) “has a pronounced antiamnestic effect, has a direct activating effect on the integrative activity of the brain , promotes memory consolidation, improves concentration of attention and mental activity, facilitates the learning process, increases the speed of information transfer between the cerebral hemispheres and the stability of brain tissue to hypoxia and toxic effects, has anticonvulsant action and anxiolytic activity, regulates the processes of activation and inhibition of the central nervous system, improves mood. “
However, it is believed that the action of this nootropic drug is comparable to the placebo effect and the expressed efficacy of this drug is not
The annual sales of Fentropil in 2016 amounted to 1 billion rubles (1.4 million packs). Representatives of the company “Valenta Farm” explained that the production of the drug was terminated “at the initiative of the rightholders” in connection with the termination of contracts for patents and trademarks.
The message posted on the website of the pharmaceutical company states that “In connection with the termination of cooperation with rights holders, Valanta Pharma JSC is not responsible for providing patients with this medication. “